This website is no longer updated
From 1 April 2026, NHS North West London and North Central London Integrated Care Board joined together to become NHS West and North London.
This means the public website is no longer updated and will be archived in the future. The professional section of the website will continue to be used for the next few months before being transferred to a new site.
Visit our new website
From 1 April 2026, please visit the new NHS West and North London website for the latest information, news and updates. The website address is www.westandnorthlondon.icb.nhs.uk
If you have saved any pages from our current site, please update your bookmarks.
NHS North West London has published new guidance for general practice on prescribing weight management medicines, including semaglutide (Wegovy®) and tirzepatide (Mounjaro®). These medicines are now available on the NHS in North West London for patients who meet specific clinical criteria.
The policy introduces a phased rollout, starting with individuals who have the highest clinical need. This includes patients with a BMI of 40 or above and multiple weight-related health conditions, as well as those with a BMI of 35 or above who require urgent weight loss for specific medical reasons such as surgery, fertility treatment, or organ transplant preparation.
Patients from South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds may qualify at lower BMI thresholds due to adjusted criteria.
Key information for patients
- Referral into services which prescribe this medication must come from the primary care clinical team, these are not self-referral services
- The guidance supports equitable access and is aligned with NHS England’s national commissioning framework.
Your GP will contact you as you become eligible. More information is available on our website.